ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Oral supplementation with Lactiplantibacillus plantarum 6.2 in rats enhances bone and epithelial tissue repair by inhibiting NF-κB protein and promoting extracellular matrix synthesis via TGF-β.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral administration of Lactiplantibacillus plantarum 6.2 mitigates acute lung injury via immunostaining of the TLR4/NF-κB pathway and reduction of IL-17 in lung tissue.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the healing and anti-inflammatory potential of the Lactiplantibacillus plantarum 6.2 (Lp62) strain, administered orally in a murine model of medication-related osteonecrosis of the jaw (MRONJ). MATERIALS AND
methodsTwenty male Wistar rats (N = 20) were randomly assigned to four groups (n = 5 per group): negative control (BASAL), healthy rats supplemented with Lp62 (LAC), experimental osteonecrosis (ONE), and osteonecrosis supplemented with Lp62 (ONE+LAC). Over an 8-week period, MRONJ was induced by intraperitoneal injections of zoledronic acid (250 μg/kg), except in the BASAL group, which received sterile 0.9% saline solution. This was followed by extraction of the left mandibular first molar. Lp62 supplementation (10⁹ CFU/mL) was administered daily by oral gavage during the 3rd and 7th weeks. At the end of the experimental period, animals were euthanized, and mandibles were examined macroscopically for exposed bone and epithelial closure. Histological evaluation included hematoxylin-eosin and Masson's trichrome staining, while immunohistochemical analysis was performed using anti-NF-κB and anti-TGF-β antibodies. Macroscopic and histomorphometric data were analyzed by one-way ANOVA followed by Tukey's or Dunnett's post hoc tests (p < 0.05).
resultsEpithelial closure and osteocyte preservation were evident in the BASAL, LAC, and ONE+LAC groups. In contrast, the ONE group exhibited no repair and showed higher NF-κB immunolabeling. Extracellular matrix (ECM) deposition was more pronounced in the Lp62-supplemented groups, which also demonstrated increased TGF-β immunolabeling.
conclusionOral supplementation with Lp62 promoted bone and epithelial regeneration, reduced NF-κB immunolabeling, and upregulated TGF-β in mandibular tissues, suggesting significant anti-inflammatory and reparative potential in experimental MRONJ lesions in rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.